Histology
Squamous Cell Carcinoma
CI-CAN-00001550SCCExplore in graph →
976 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001550SCCExplore in graph →
Clinical trials
2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02124850 | A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab | terminated | Phase 1 | 18 | CelgeneINDUSTRY | 1 | Oct 25, 2019 | clinicaltrials |
| Efficacy of SU 011248 in Head And Neck Carcinoma |
| terminated |
| Phase 2 |
| 54 |
| Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER |
| 2 |
| Sep 19, 2019 |
| clinicaltrials |
| NCT01611662 | Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | terminated | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT00262821 | Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer | terminated | Phase 3 | 402 | National Cancer Institute (NCI)NIH | 2 | Jul 23, 2019 | clinicaltrials |
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung(PrE0504) | terminated | Phase 1 / Phase 2 | 13 | PrECOG, LLC.OTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01248299 | Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.(E-DIS) | terminated | Phase 2 | 105 | Centre Oscar LambretOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT00507702 | Identification of Key Blood Molecular Markers for Immunotherapy | terminated | — | 191 | Stanford UniversityOTHER | 1 | Apr 18, 2019 | clinicaltrials |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | terminated | Phase 2 | 1 | University of ChicagoOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03179956 | Impact of Ribociclib on Head and Neck Squamous Cell Cancer | terminated | Early Phase 1 | 1 | Fox Chase Cancer CenterOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT02388932 | Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer | terminated | N/A | 3 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT02205398 | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | terminated | Phase 1 | 13 | Novartis PharmaceuticalsINDUSTRY | 7 | Jan 22, 2019 | clinicaltrials |
| NCT03246685 | Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD | terminated | Phase 2 | 1 | HiberCell, Inc.INDUSTRY | 1 | Dec 14, 2018 | clinicaltrials |
| NCT01764607 | Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma | terminated | Phase 2 | 1 | University of FloridaOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT03223662 | Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2018 | clinicaltrials |
| NCT01732640 | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | terminated | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT01852292 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | terminated | Phase 2 | 157 | Novartis PharmaceuticalsINDUSTRY | 18 | Jul 24, 2018 | clinicaltrials |
| NCT01164566 | Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy | terminated | N/A | 6 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02552550 | Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx | terminated | — | 12 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT00901537 | Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer | terminated | Phase 1 | 8 | Loma Linda UniversityOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT01823679 | Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin | terminated | Phase 2 | 2 | Stanford UniversityOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT01627379 | Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer(POWER) | terminated | Phase 3 | 300 | AIO-Studien-gGmbHOTHER | 1 | Mar 2, 2018 | clinicaltrials |
| NCT01456143 | Optical Imaging of Head and Neck Cancer | terminated | N/A | 33 | Sharmila Anandasabapathy, MDINDIV | 1 | Feb 1, 2018 | clinicaltrials |
| NCT02407561 | Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays | terminated | — | 3 | Castle Biosciences IncorporatedINDUSTRY | 1 | Jan 25, 2018 | clinicaltrials |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | terminated | Phase 2 | 8 | Nina BhardwajOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01488318 | Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma | terminated | Phase 2 | 21 | Julie E. Bauman, MD, MPHOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT01051791 | Phase II Study of RAD001 Head and Neck Cancer | terminated | Phase 2 | 13 | Julie E. Bauman, MD, MPHOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT01221753 | Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study | terminated | Phase 2 | 7 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00570674 | Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck | terminated | Phase 1 / Phase 2 | 29 | Dana-Farber Cancer InstituteOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT00070317 | Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer | terminated | N/A | 102 | Gynecologic Oncology GroupNETWORK | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00400205 | Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil | terminated | Phase 2 | 14 | Emory UniversityOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02076243 | Treatment With Nab-paclitaxel in Cutaneous SCC | terminated | Phase 2 | 2 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT02068157 | Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer | terminated | Phase 2 | 3 | Roswell Park Cancer InstituteOTHER | 1 | Oct 11, 2017 | clinicaltrials |
| NCT02538627 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | terminated | Phase 1 | 5 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT01740375 | Role of Esophagectomy in Complete Responders to CCRT(ESOPRESSO) | terminated | Phase 3 | 486 | Asan Medical CenterOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT00591149 | Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer | terminated | Phase 2 | 16 | University of Kansas Medical CenterOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01303237 | A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck(PMS LAD SCCHN) | terminated | — | 88 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jun 9, 2017 | clinicaltrials |
| NCT00632203 | Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) | terminated | Phase 2 | 53 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT01794845 | Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma | terminated | Phase 2 | 5 | University of MiamiOTHER | 1 | May 11, 2017 | clinicaltrials |
| NCT01142869 | An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | terminated | — | 133 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | May 8, 2017 | clinicaltrials |
| NCT02045186 | Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) | terminated | N/A | 1 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT02196168 | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | May 3, 2017 | clinicaltrials |
| NCT01267240 | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 2 | Apr 14, 2017 | clinicaltrials |
| NCT00392665 | Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT00490061 | Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy | terminated | Phase 2 | 17 | Quynh-Thu LeOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00443261 | Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 1 | 1 | University of Kansas Medical CenterOTHER | 1 | Feb 27, 2017 | clinicaltrials |
| NCT00903461 | Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 | 7 | University of PittsburghOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00937612 | Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk | terminated | N/A | 10 | Chang Gung Memorial HospitalOTHER | 1 | Feb 8, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Dec 17, 2019source: clinicaltrials